The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

Just eight seconds into the start of the 2025 award show season, Nikki Glaser, the host of the 82nd Golden Globes, dubbed the ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The FDA on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug ...

According to the study, participants taking Zepbound lost an average of 20.2% of their starting weight after 72 weeks, ...

( NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans ...

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.

Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.

Eli Lilly announced Tuesday single-dose vials of weight loss drug Zepbound are now available for patients with a prescription ...